Personalized Neoantigen Vaccines in Melanoma: Current Workflow and Adjuvant Opportunities

Behzad Mansoori ¹ , Mohsen Mohammadi ² *

Cited by CrossRef:

Submit Your Paper Editorial Board Editorial Policies Aims and Scope For Authors Archive

Acceptance Rate: 35%
Submission to First Decision: 20 Days
Received to Acceptance: 60 Days
Acceptance to Publication: 40 Days
*Average article statistics from the last 12 months of data.